The work, published in Neurobiology of Aging, analyzed brain-scan data from two sizable groups totaling more than 1,300 participants. Participants reported poorer sleep quality, and the researchers focused on network connectivity patterns rather than symptoms alone. The goal was to identify whether the same “sleep-related” brain changes look the same in young versus older adults.

The findings reveal a striking age-dependent shift. In college-age participants, poor sleep was linked to overconnected regions involved in movement, suggesting the brain and body may be in a state that is not primed for falling asleep. In adults aged 65 and older, the pattern flipped: movement-related connections were underconnected, while hyperconnectivity emerged in networks tied to cognition.

Sex-specific effects were especially prominent in older women. Their poor sleep correlated with abnormal hyperconnectivity between the Default Mode Network (DMN)—often associated with internally directed thought—and the Frontal Parietal Network (FPN)—a system important for sustained attention and working memory. This DMN–FPN pattern tracked with worse memory performance.

Importantly, the DMN–FPN abnormality resembles wiring characteristics described in preclinical, silent stages of Alzheimer’s disease. While this does not prove causation, it raises concern that chronic sleep disruption may interact with early markers of neurodegenerative risk.

The study also highlights a “chicken-and-egg” problem: do connectivity changes precede sleep loss, or does sleep disruption drive connectivity alterations? Longitudinal associations suggested that abnormal hyperconnectivity may predict subsequent cognitive decline, implying that sleep disturbance could set the stage for later brain-health consequences.

Researchers note plausible mechanisms, including habituation to hyperarousal or coping strategies such as sleep medication use. Another candidate is rumination—persistent, anxiety-linked “running thoughts” before bedtime—which may keep the brain in an agitated state instead of a calm one.

For younger adults, strategies that reduce pre-sleep arousal, such as journaling, may help. For older adults, the pathways remain less clear, so clinicians advise speaking with a physician rather than self-treating.

If connectivity changes can indeed occur before major sleep loss, targeted efforts to strengthen network function could become a future intervention route. For now, the data reinforce a viral, widely relevant message: sleep quality is a measurable brain signal, and protecting it may help safeguard cognitive aging.

Subject of Research: People
Article Title: Sleep quality is associated with default mode and salience network connectivity differently across age and sex
News Publication Date: 6-May-2026
Web References: http://dx.doi.org/10.1016/j.neurobiolaging.2026.05.002
References: Neurobiology of Aging (6-May-2026) — “Sleep quality is associated with default mode and salience network connectivity differently across age and sex”
Image Credits:
Keywords: sleep quality, brain connectivity, default mode network, frontal parietal network, neurobiology of aging, hyperconnectivity, cognitive decline, Alzheimer’s risk

Dr. Guldner’s research delves deeply into the complex interplay of proteostasis within neurons—a critical cellular system responsible for protein synthesis, folding, recycling, and degradation. Maintaining proteostasis is essential for neuronal longevity, particularly given the decades-long lifespan of these cells. Alterations in these pathways lead to protein aggregation and cellular dysfunction, hallmarks observed in age-associated neurodegenerative disorders like Alzheimer’s disease. His laboratory aims to elucidate how disruptions in these finely tuned proteostatic mechanisms contribute to the early phases of brain aging, with the ultimate goal of targeting these processes to prevent or mitigate cognitive decline.

Another central pillar of Guldner’s work focuses on neuroimmune interactions within the brain’s microenvironment. The brain’s immune system is largely governed by microglia, resident macrophage-like cells that perform surveillance and response functions. By exploring how microglia detect and respond to neuronal stress signals—especially those elicited by aging—Dr. Guldner’s research sheds light on the immunological crosstalk that shapes brain health. His recent discoveries highlight the accumulation of neuron-derived synaptic proteins within microglia as a potential early biomarker of synaptic dysfunction and impending neurodegeneration, offering a novel perspective on the molecular exchanges that underpin brain aging.

Earlier in 2026, Dr. Guldner published a pivotal first-author paper in Nature, which demonstrated that aging facilitates the translocation of specific synaptic proteins from neurons into microglial cells. This protein transfer not only exemplifies a previously underappreciated route of molecular communication but also implicates the immune surveillance system as both a responder and potential mediator in neurodegenerative disease progression. This insight adds a new layer of complexity to the understanding of proteomic shifts within the aging brain’s microenvironment, suggesting new molecular targets for intervention.

Dr. Guldner’s interdisciplinary expertise extends beyond neurodegeneration. His work has also rigorously examined immune modulation mechanisms in cancer brain metastases, bringing a unique translational perspective to his studies of brain immune dynamics. This cross-disease approach equips him with a broader understanding of the immune system’s dualistic roles in maintaining brain homeostasis and contributing to pathology across different disease paradigms, thereby enabling innovative strategies that may apply to multiple neurological conditions.

The appointment of Dr. Guldner was facilitated through the generosity of the Ray and Dagmar Dolby Family Fund, spearheaded by David Dolby, CEO of Dolby Family Ventures. This philanthropic support is instrumental in recruiting pioneering scientists who can push the boundaries of foundational biomedical research. According to Salk Institute President Dr. Gerald Joyce, this strategic investment underscores the institute’s commitment to tackling early biological questions that form the basis for medical breakthroughs, especially in understanding how complex cellular processes evolve with age and yield disease.

In his own words, Dr. Guldner is energized by the collaborative scientific culture at Salk, where fundamental questions about life and aging are pursued with rigor and creativity. He emphasizes the importance of integrating multidisciplinary expertise to decode the cellular machinery of brain aging, an approach he believes will pave the way for new preventive and therapeutic modalities against Alzheimer’s and related disorders. His new laboratory will prioritize the development and application of sophisticated tools designed to monitor protein dynamics and cell-to-cell signaling in vivo, delivering unprecedented insights into the molecular substrates of brain aging.

The developmental trajectory that led to Dr. Guldner’s groundbreaking work includes a Bachelor of Science in biology from Moravian College, a doctoral degree from the University of Notre Dame, and postdoctoral training at Stanford University. His accomplishments have been recognized by the National Institute on Aging with the prestigious K99/R00 Pathway to Independence Award, signaling his potential to become a leading figure in neurobiology. This award supports his transition to independent research, underpinning his efforts to innovate in the study of aging and neuroimmune interactions.

As the Salk Institute continues to deepen its focus on neurodegeneration and brain aging, Dr. Guldner’s research is expected to stimulate cross-disciplinary initiatives encompassing immunobiology, cancer research, and molecular gerontology. His work exemplifies a modern neuroscience approach that combines cellular biology with systems-level understanding. Through novel molecular imaging and proteomic techniques, his studies will map the dynamic exchanges shaping the aging brain’s environment, offering vital clues into the earliest cellular events that foreshadow cognitive impairment.

David Dolby highlighted the pressing need for early-stage research and new technologies that allow scientists to visualize and interpret biological changes with heightened precision. The donation from the Dolby Family Fund, which enabled Dr. Guldner’s recruitment, is emblematic of this vision—empowering foundational discovery that promises to translate into clinical advances. Dolby expressed optimism that supporting investigators like Dr. Guldner will accelerate progress in developing innovative therapies for Alzheimer’s disease and other dementias that currently lack effective treatments.

Dr. Guldner’s vision integrates fundamental mechanistic exploration with translational aspirations, aiming to construct a detailed molecular and cellular framework of brain aging. By decoding how proteins and immune cells interact in the aging brain, his research endeavors to identify molecular choke points amenable to therapeutic targeting. Such interventions could transform how neurodegenerative diseases are diagnosed and managed, emphasizing prevention grounded in a deep understanding of brain cellular biology.

As he prepares to establish his laboratory at Salk, Dr. Guldner plans to foster collaborations that cut across traditional disciplinary boundaries. His work will leverage cutting-edge proteostasis assays, advanced neuroimmune imaging, and single-cell molecular profiling to expand the frontiers of brain aging research. Through integrated experimental approaches, his team will illuminate the mechanisms orchestrating neuronal proteome maintenance and microglial function across lifespan, setting the stage for innovative research into cognitive resilience.

The recruitment of Dr. Ian Guldner signals a promising era for the Salk Institute’s quest to decipher the biology of aging and neurodegeneration. His expertise and pioneering research align with the institute’s ethos of seeking fundamental biological truths as a foundation for transformative medical breakthroughs. As brain aging is a universal process with increasing societal impact, initiatives like Dr. Guldner’s are critical to fulfilling the urgent need for novel interventions that sustain cognitive health and quality of life into advanced age.

Subject of Research: Brain Aging, Alzheimer’s Disease, Cellular Communication Mechanisms, Proteostasis, Neuroimmune Interactions
Article Title: Not provided in the original content
News Publication Date: May 7, 2026
Web References: https://www.nature.com/articles/s41586-025-09987-9
Image Credits: Luci Valentine Photography
Keywords: Brain aging, Alzheimer’s disease, proteostasis, microglia, neurodegeneration, cellular communication, immune surveillance, protein dynamics, neuroimmune interactions, cognitive health, neurobiology, Salk Institute

This year’s cohort of awardees embodies a diverse range of scientific inquiries, exemplifying the multifaceted approach required to decipher the complex biological and molecular processes underlying aging. Their investigations extend from cellular metabolism and immune regulation to neurobiology and regenerative medicine, reflecting AFAR’s commitment to supporting high-impact research across the full spectrum of aging biology.

One highlighted recipient, Dr. Jacob Brown from Florida State University, is exploring the therapeutic potential of oxylipins in ameliorating muscle atrophy induced by disuse during aging. Oxylipins are lipid-derived signaling molecules implicated in inflammation and tissue repair. Dr. Brown’s work seeks to determine whether modulating these pathways might enhance recovery from muscle deterioration, a significant contributor to frailty in elderly populations. This could pave the way for novel interventions targeting muscle resilience in aging individuals.

At Harvard Medical School, Dr. Ang Cui is delving into the intricacies of cytokine signaling and its influence on hematopoietic stem cell (HSC) fate decisions with age. Hematopoietic stem cells are responsible for maintaining blood cell populations, but their function declines as we age, contributing to immunosenescence and heightened disease susceptibility. Dr. Cui’s project aims to decode how cytokine milieus direct HSC differentiation and renewal, potentially uncovering molecular targets to rejuvenate aged immune systems.

Another promising investigation by Dr. Madison Doolittle at the University of Connecticut Health Center focuses on the phenomenon of premature aging and persistent cellular senescence following tissue injury resolution. Senescent cells—cells that cease dividing but remain metabolically active—accumulate with age and contribute to chronic inflammation and tissue dysfunction. Dr. Doolittle’s research attempts to discern how these residual senescent cells after injury might accelerate aging processes, providing insights crucial for developing senolytic therapies that selectively clear harmful senescent cells.

Neuroimmunology is represented by Dr. Sija He from the University of Texas Health San Antonio, who is investigating brain innate immunity’s role in regulating systemic aging. The central nervous system’s immune environment profoundly influences peripheral organ function and systemic homeostasis. Dr. He’s research may elucidate mechanisms by which neuroimmune interactions impact aging trajectories, potentially informing novel interventions for age-associated neurological and systemic disorders.

At the University of California Riverside, Dr. Huimin Zhang is advancing knowledge on T cell aging, specifically looking at the epigenetic regulation mediated by the transcription factor HELIOS and its impact on follicular helper T (TFH) cell differentiation. TFH cells are critical for adaptive immunity and vaccine responses, which wane with age. Understanding HELIOS’s role could reveal epigenetic manipulation strategies to bolster immune competence in older adults.

Dr. Meng Zhang at Scripps Research is pioneering the use of spatial multi-omics—the combined analysis of spatially resolved transcriptomics, proteomics, and metabolomics—to unravel neuro-immune crosstalk. His work captures the dynamic molecular dialogues within aging tissues, aiming to identify key signaling networks that drive age-related functional decline. This integrative approach promises a comprehensive mapping of aging biology at unprecedented resolution.

AFAR’s Grants for Junior Faculty are not only a source of financial backing but also a recognition of scientific promise at a turning point in researchers’ careers. Stephanie Lederman, EdM, Executive Director of AFAR, emphasizes that this grant program is “a core grant program since AFAR’s inception,” signifying its foundational role in nurturing talent that has continually pushed the frontier of aging research. These grants serve as essential catalysts enabling scientists to generate preliminary data, publish influential findings, and secure future funding.

The support system behind these grants is robust, with backing from philanthropic foundations such as the Marion Esser Kaufmann Foundation and the Hearst Foundations providing targeted underwriting. Additionally, the AFAR Board of Directors, along with numerous anonymous donors and charitable trusts, contribute to a diversified funding portfolio ensuring program sustainability. This collaborative funding ecosystem enables a high level of competitive support that sustains scientific innovation.

For over four decades, AFAR has been at the forefront of biomedical aging research, distributing over $225 million to more than 4,500 investigators across premier institutions. The organization’s strategic role transcends grantmaking; AFAR also coordinates interdisciplinary research networks and public-private partnerships, fostering a collaborative environment that accelerates translational breakthroughs. In 2025 alone, AFAR anticipates allocating over $12 million in funding to nearly 80 investigators, reflecting sustained commitment to combating age-related diseases and improving healthspan.

The scientific insights emerging from AFAR-supported projects increasingly reveal the plasticity of aging processes at the cellular and molecular levels. By modifying fundamental pathways such as inflammation, epigenetic regulation, and stem cell function, researchers are demonstrating that aging is not a fixed destiny but a malleable biological state. This paradigm shift lays the groundwork for therapies that could delay multiple chronic diseases simultaneously, extending both lifespan and quality of life.

AFAR’s portfolio is driving a new era in aging research, where innovative methodologies like spatial multi-omics, advanced immunophenotyping, and targeted epigenetic interventions converge. The junior faculty currently funded through this program embody the next generation of thought leaders poised to revolutionize geroscience. Their work holds the promise of transforming clinical paradigms by enabling early interventions that preserve tissue function, enhance immune resilience, and mitigate degenerative processes.

Ultimately, these grants represent more than financial support; they symbolize a strategic investment in the future of aging science. By empowering early-career scientists to pursue high-risk, high-reward studies, AFAR is catalyzing knowledge that will unlock therapeutic potentials and shape public health trajectories. As our global population ages, this pioneering research is vital to ensuring that longer lives are paired with sustained health and vitality.

For further information about the Grants for Junior Faculty and other research support opportunities, interested parties can visit AFAR’s official website, where detailed program descriptions and application guidelines are available. This transparent and accessible approach fosters broader engagement with the aging research community, encouraging collaborative innovation to tackle one of the most pressing biomedical challenges of our time.

—

Subject of Research: Biology of Aging and Age-Related Mechanisms
Article Title: Emerging Breakthroughs in Aging Biology: AFAR’s 2025 Junior Faculty Grants Propel Next-Generation Research
News Publication Date: 2025
Web References: https://www.afar.org/grants/afar-research-grants-1-2
References: Information sourced from AFAR official grant announcements and investigator profiles
Image Credits: AFAR Publications
Keywords: Aging, Biology of Aging, Geroscience, Oxylipins, Hematopoietic Stem Cells, Cellular Senescence, Neuroimmunity, Epigenetic Regulation, Spatial Multi-omics, Junior Faculty Grants

The decline in cognitive function and progressive brain degeneration mark some of the most challenging hurdles in the biology of aging. Despite the profound societal impact of these conditions, therapeutic options remain limited and often ineffective. Dr. Moore’s innovative research centers around the application of extracellular vesicles (EVs)—nano-sized particles secreted by young stem cells—as a novel biological intervention to rejuvenate aging brains. Prior investigations have uncovered compelling evidence that these EVs can significantly enhance memory performance and brain connectivity in aged model organisms, suggesting a potential paradigm shift toward biologically inspired cognitive restoration.

Extracellular vesicles represent a class of membrane-bound vesicles released by many cell types, including stem cells, which facilitate intercellular communication by transporting proteins, lipids, and nucleic acids such as microRNA. Their ability to modulate cellular function and influence tissue repair processes has garnered increasing attention. Crucially, Dr. Moore’s prior studies suggest a fascinating twist in the story: EVs derived from female stem cell donors exhibit superior efficacy in mitigating age-related brain dysfunction compared to their male counterparts, hinting at underlying biological mechanisms that could pivot therapy toward a sex-specific precision medicine approach.

The current phase of Dr. Moore’s research delves into the molecular and functional differences between EVs sourced from male and female donors. By systematically evaluating their relative capacities to reverse neuropathological hallmarks associated with aging—including synaptic loss, neuroinflammation, and accumulation of misfolded proteins—her laboratory aims to elucidate the mechanisms driving differential therapeutic outcomes. These insights promise to unveil novel biomarkers and molecular targets, ultimately guiding the development of sex-tailored interventions to not only slow cognitive decline but possibly offer protection against Alzheimer’s disease and related dementias.

Dr. Moore brings a multiplicity of expertise to this endeavor. Beyond her professorship, she serves as associate dean of research, interim director of the Laboratory of Interventions for Cortical Injury and Cognitive Decline, and co-investigator in the Laboratory of Cognitive Neurobiology. Her extensive background in studying the neurobiological underpinnings of higher cognitive functions, and how they are perturbed by aging, hypertension, and brain injury, equips her to navigate the complex interface of basic neuroscience and translational therapeutic development.

Her contributions are not confined to the laboratory. Demonstrating a sustained commitment to education and institutional leadership, Dr. Moore spearheaded the creation and development of two influential master’s programs at Boston University: the Biomedical Forensic Sciences Program launched in 2006, and the MS in Forensic Anthropology program initiated in 2008, where she has served as director since its inception. Her role on the Institutional Animal Care and Use Committee (IACUC) since 2010, including terms as scientific member, vice chair, and chair, reflects a dedication to ethical standards in research involving animal models.

At the core of Dr. Moore’s scientific philosophy lies a commitment to translational impact—transforming fundamental discoveries about extracellular vesicle biology into therapeutic realities. The challenge of cognitive aging is multifaceted, with neuropathology characterized by complex interactions among neuronal loss, synaptic dysfunction, glial activation, and vascular alterations. The ability of EVs to carry multifarious cargos capable of modulating these pathways simultaneously places them at the forefront of next-generation neurotherapeutics.

Detailed characterization of EV content, such as microRNAs, cytokines, and trophic factors, is pivotal to understanding their effect. Variations in these molecular constituents between male-derived and female-derived EVs may illuminate sex-specific pathways in neuroprotection and repair. By deploying state-of-the-art proteomic and transcriptomic analyses combined with functional behavioral assays in non-human primate models, Dr. Moore’s project seeks to bridge the translational gap from rodent studies toward human applicability, enhancing clinical relevance and therapeutic potential.

Non-human primates represent an unparalleled model for studying human neurobiology due to their closer genetic, anatomical, and cognitive similarities. Aging-related neuropathological processes in these models mirror those seen in humans more accurately than rodents, particularly regarding higher-order cognitive functions vulnerable to Alzheimer’s and related disorders. This renders Dr. Moore’s research uniquely positioned to generate data that can accelerate clinical trials and pave the way for regulatory approval of EV-based therapies.

The anticipated outcomes of this research extend beyond academic novelty. Demonstrating that sex-specific EVs can reverse or slow cognitive decline offers a new avenue for developing personalized medicine strategies that consider donor-recipient sex dynamics, a critical factor often overlooked in therapeutic development. Such precision approaches could revolutionize aging care protocols, reduce the growing societal burden of dementia, and enhance quality of life for an aging global population.

Dr. Moore’s academic journey—from receiving her bachelor’s degree in psychology from the University of Calgary to earning her doctorate in Anatomy and Neurobiology at Boston University in 2000—has been marked by a continuum of rigorous research and clinical relevance. Her multidisciplinary expertise combines neurobiology, geriatrics, and forensic science, reflecting an integrative approach to understanding and combating the biological challenges posed by aging.

As this significant NIH-funded initiative unfolds over the next five years, the scientific community and the public alike watch with anticipation. If successful, Dr. Moore’s work will not only deepen our understanding of aging brain biology but also open the door to novel regenerative therapies grounded in cutting-edge extracellular vesicle science. The era of sex-specific, precision neurotherapeutics may soon arrive, transforming how we approach age-related cognitive impairments and neurodegenerative diseases.

Subject of Research: Extracellular vesicle therapy for age-related neuropathology and cognitive decline in non-human primates

Article Title: Not provided

News Publication Date: Not provided

Web References: Not provided

References: Not provided

Image Credits: Not provided

Keywords: Diseases and disorders; Health and medicine

Neurons and glia have historically been viewed as distinct entities, with neurons responsible for electrical signaling and glia serving primarily supportive roles. However, emerging evidence dismantles this simplistic view, unveiling glia as dynamic contributors to neural circuitry maintenance and modulation. The current research shifts this understanding further by demonstrating that neurons actively send molecular signals to glia using extracellular vesicles—nano-sized packets capable of shuttling proteins and RNA—thereby influencing glial function at a distance.

Focusing on the nematode Caenorhabditis elegans, an organism prized for its transparent anatomy and genetic tractability, the investigators pinpointed the amphid sensory organ as a model system for dissecting neuron-glia interactions. Intriguingly, they observed that sensory neurons within this organ age heterogeneously, presenting differential rates of functional decline. This observation led them to hypothesize that intercellular communication between neurons and glia might mediate these diverse aging trajectories.

Central to this discovery is the role of heat shock proteins (HSPs), traditionally characterized as molecular chaperones that maintain protein integrity under stress conditions. Wu et al. demonstrate that beyond their canonical functions, HSPs act as signaling molecules transmitted via extracellular vesicles from neurons to glia. This unconventional mode of communication triggers the activation of the IRE1–XBP1 pathway within glial cells—a pivotal component of the unfolded protein response (UPR) that maintains cellular homeostasis under stress.

The activation of this glial signaling cascade stimulates the transcription of genes coding for chondroitin synthases, enzymes involved in synthesizing chondroitin sulfate proteoglycans. These molecules contribute to the extracellular matrix architecture surrounding neurons, providing a neuroprotective environment that buffers against aging-related degradation. This neuron-to-glia signaling axis thus forms a feedback loop that enables glial cells to adapt their protective functions in response to neuronal aging.

Understanding the mechanics of extracellular vesicle-mediated protein transfer in this context reshapes how we envision intercellular dialogue in the nervous system. Extracellular vesicles, including exosomes and microvesicles, have gained attention for their roles in intercellular communication across various tissues. Here, their utility is unveiled as vehicles for direct protein transfer that modulates gene expression and rejuvenates glial support functions during the aging process.

The choice of the C. elegans model is strategic, leveraging its well-characterized sensory neurons and glia, combined with advanced molecular tools that reveal dynamics invisible in more complex organisms. Such insights bear translational potential, suggesting that similar neuron-glia communication networks could exist in higher organisms, including humans, influencing neurodegeneration and brain aging.

Moreover, the engagement of heat shock proteins as signaling molecules provides a fresh perspective on their physiological roles. Rather than merely acting intracellularly to refold misfolded proteins, HSPs dispatched through vesicles represent a form of stress communication that coordinates cellular defenses across cell types. This conceptual advance broadens the framework within which we understand proteostasis networks in brain aging.

The study also highlights the importance of the IRE1–XBP1 axis in glial cells. This pathway, a key player in the unfolded protein response, safeguards cellular function by resolving endoplasmic reticulum stress. Its activation through neuron-derived signals underscores a cooperative system where neurons and glia share burdens of proteostasis maintenance, adjusting their states dynamically in response to aging cues.

Crucially, the upregulation of chondroitin synthases in glia initiates structural remodeling of the extracellular environment. Chondroitin sulfate proteoglycans participate in modulating plasticity and protection within the nervous system. By linking molecular signaling with extracellular matrix synthesis, the study connects intracellular stress responses to broader tissue-level resilience.

This research also raises fascinating questions about the temporal dynamics of aging across different neuronal populations. Why particular sensory neurons age at different rates dependent on glial crosstalk opens avenues for exploring heterogeneity in neurodegenerative vulnerability. Targeting these intercellular signaling pathways may one day inform therapeutic strategies to delay or mitigate age-related cognitive decline.

The implications extend to understanding neuroinflammatory pathways, given that glial cells orchestrate immune responses within the brain. Modulation of glial states by neuron-derived HSPs could influence inflammatory profiles, impacting disease progression in conditions like Alzheimer’s and Parkinson’s diseases, where defective proteostasis and glial dysregulation are prominent.

The elegance of this study lies in its integration of cellular biology, molecular neuroscience, and aging research, showcasing a previously hidden level of complexity in nervous system communication. It suggests that maintaining brain health over the lifespan depends on the sophistication of intercellular signaling, with extracellular vesicle-mediated protein transfer emerging as a crucial mediator.

Looking ahead, these findings invite further inquiry into whether artificially enhancing neuron-to-glia HSP transfer or mimicking its effects could bolster neuroprotection. Such approaches could open innovative therapeutic avenues, transforming aging from an inexorable decline into a manageable process.

In conclusion, Wu et al. have provided a compelling narrative that redefines heat shock proteins as more than mere guardians against cellular stress. Their role as signaling mediators facilitating neuron-glia cross-talk via extracellular vesicles in C. elegans reveals a mechanistic underpinning for differential neuronal aging, highlighting new avenues for understanding and potentially intervening in brain aging.

This pioneering work offers fresh insights into the molecular choreography between neurons and glia, shining light on the sophisticated strategies that nervous systems deploy to maintain function and viability across the lifespan. As the scientific community continues unraveling these pathways, the boundary between neuron and glia is redrawn, emphasizing their partnership as a cornerstone of brain resilience and longevity.

Subject of Research: Neuron-glia communication mechanisms during aging in Caenorhabditis elegans, focusing on heat shock protein-mediated signaling and glial activation pathways.

Article Title: Heat shock proteins function as signaling molecules to mediate neuron–glia communication in C. elegans during aging.

Article References:
Wu, J., Yarmey, V.R., Yang, O.J. et al. Heat shock proteins function as signaling molecules to mediate neuron–glia communication in C. elegans during aging. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-01989-0

Image Credits: AI Generated